Zhang Lijie, Zhao Xiaomin, Gao Xianghong, Qin Hao, Chen Feng, Lin Zhijuan
Key Laboratory for Immunology in Universities of Shandong Province, School of Basic Medicine Sciences, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Weifang Hospital of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, 261001, Shandong, China.
Cancer Cell Int. 2025 Mar 7;25(1):80. doi: 10.1186/s12935-025-03713-1.
High mobility group A1 (HMGA1) is a class of non-histone chromosomal protein and is highly expressed in the embryonic period and many tumors. It is involved in multiple hallmarks of tumors and affects the occurrence and progression of tumors. Nowadays, many non-coding RNAs (ncRNAs), such as miRNA, lncRNA, and circRNA, have been found to play a crucial role in HMGA1 regulation. Moreover, some ncRNAs are reported to be the downstream effectors of HMGA1. They interact with each other to affect multiple hallmarks of cancer and targeting ncRNAs or HMGA1 may provide potential strategies for cancer therapy. In this review, we give an overview of recent studies describing the crosstalk between oncogenic HMGA1 and ncRNAs. We also point out the impact of this interaction on the biological behavior of tumors and their potential in tumor therapy in order to offer potential implications and directions for both basic science and clinical applications.
高迁移率族蛋白A1(HMGA1)是一类非组蛋白染色体蛋白,在胚胎期和许多肿瘤中高表达。它参与肿瘤的多个特征,影响肿瘤的发生和发展。如今,许多非编码RNA(ncRNA),如miRNA、lncRNA和circRNA,已被发现在HMGA1调控中起关键作用。此外,据报道一些ncRNA是HMGA1的下游效应物。它们相互作用以影响癌症的多个特征,靶向ncRNA或HMGA1可能为癌症治疗提供潜在策略。在这篇综述中,我们概述了最近描述致癌性HMGA1与ncRNA之间相互作用的研究。我们还指出了这种相互作用对肿瘤生物学行为的影响及其在肿瘤治疗中的潜力,以便为基础科学和临床应用提供潜在的启示和方向。